Nivolumab Ups Overall Survival in Head, Neck Cancer

This article originally appeared here.
Share this content:
Nivolumab Ups Overall Survival in Head, Neck Cancer
Nivolumab Ups Overall Survival in Head, Neck Cancer

MONDAY, Oct. 10, 2016 (HealthDay News) -- Nivolumab is associated with longer overall survival than standard single-agent therapy in patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, according to a study published online Oct. 9 in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Medical Oncology Congress, held from Oct. 7 to 11 in Copenhagen, Denmark.

Robert L. Ferris, M.D., Ph.D., from the University of Pittsburgh Medical Center and Cancer Institute, and colleagues conducted a randomized trial involving 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within six months after platinum-based chemotherapy. Patients were randomized in a 2:1 ratio to nivolumab every two weeks or a standard single-agent systemic therapy (methotrexate, docetaxel, or cetuximab).

The researchers found that the median overall survival was 7.5 and 5.1 months in the nivolumab and standard therapy groups, respectively. Overall survival was significantly longer with nivolumab (hazard ratio for death, 0.70; 97.73 percent confidence interval, 0.51 to 0.96); the estimates of one-year survival were 36.0 versus 16.6 percent for nivolumab versus standard therapy. The median progression-free survival was 2.0 and 2.3 months for nivolumab and standard therapy, respectively (hazard ratio for disease progression or death, 0.89; 95 percent confidence interval, 0.70 to 1.13).

"Treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy," the authors write.

The study was funded by Bristol-Myers Squibb, the manufacturer of nivolumab.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

Higher proportion of patients achieved a ≥50 percent reduction in mean monthly migraine days

AAN: New Drug May Help Infants With Spinal Muscular Atrophy

AAN: New Drug May Help Infants With Spinal ...

RG7916 increases survival motor neuron protein level, with 6.5-fold increase noted with highest dose

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small overall effect size for frequent and heavy cannabis use among adolescents, young adults

is free, fast, and customized just for you!

Already a member?

Sign In Now »